Company news
Proteomics International Laboratories Ltd. (ASX:PIQ) news
Proteomics International Laboratories Ltd. news releases on 6ix. Latest, Sep 23, 2024: Esophageal cancer diagnostic delivers excellent results
Press releases — page 2
Esophageal cancer diagnostic delivers excellent results
September 22, 2024
Update on commercialisation of PromarkerD in the USA
September 10, 2024
Groundbreaking results for type 1 diabetes and kidney health
August 22, 2024
June 2024 Quarterly Activities Report and Appendix 4C
July 29, 2024
Eurobio Scientific to sell PromarkerD DKD test in France
June 23, 2024
Proteomics appoints medical devices sales agency for Europe
June 16, 2024
March 2024 Quarterly Activities Report and Appendix 4C
April 16, 2024
Proteomics signs with Oxford Univ to validate test for Endo
March 24, 2024
PromarkerD US commercialisation & Promarker pipeline update
March 17, 2024
European patent granted for OxiDx technology
February 27, 2024
Study validates biomarkers for oesophageal cancer blood test
January 31, 2024
Study validates biomarkers for endometriosis blood test
January 31, 2024
Proteomics to raise $6.5m through Institutional Placement
January 22, 2024
December 2023 Quarterly Activities Report and Appendix 4C
January 22, 2024
PromarkerD licence with Omics Global extended to Chile
December 19, 2023
US Medicare confirms reimbursement price for PromarkerD
November 21, 2023
Proteomics receives $1.85 million in R&D tax incentive
November 8, 2023
September 2023 Quarterly Activities Report and Appendix 4C
October 25, 2023
Reinstatement to Quotation
September 28, 2023
PromarkerD US reimbursement price & Aus regulatory decision
September 28, 2023
Suspension from Quotation
September 18, 2023
New oesophageal cancer test presented at global conference
September 7, 2023
OxiDx platform technology secures patent in Japan
September 3, 2023
June 2023 Quarterly Activities Report and Appendix 4C
July 23, 2023
Sonic Healthcare USA signs licence for PromarkerD in the US
May 10, 2023
World Endometriosis Congress - New diagnostic test showcased
May 4, 2023
Canagliflozin lowers PromarkerD DKD risk prediction scores
May 2, 2023
March 2023 Quarterly Activities Report and Appendix 4C
April 26, 2023
Proteomics renews ISO 13485 and ISO 17025 accreditations
April 16, 2023
New endometriosis test presented at international conference
March 24, 2023
PromarkerD application for Australian MBS to be resubmitted
March 15, 2023
Distribution agreement for PromarkerD in Britain extended
February 14, 2023
December 2022 Quarterly Activities Report and Appendix 4C
January 30, 2023
Letter of intent with Sonic Healthcare USA extended
January 30, 2023
CPT PLA reimbursement code approved in US for PromarkerD
January 2, 2023
UK NICE publishes Medtech Innovation Briefing on PromarkerD
December 13, 2022
AGM Chairmans Address and Investor Presentation
November 24, 2022
PromarkerD patent granted in Hong Kong
November 10, 2022
September 2022 Quarterly Activities Report and Appendix 4C
October 30, 2022
Precision diagnostics facility receives $2m funding boost
October 19, 2022
Proteomics receives $1.7 million in R&D tax incentive
October 16, 2022
New Oesophageal Cancer Diagnostic shows strong performance
September 26, 2022
OxiDx launched to maximise oxidative stress technology
August 28, 2022
Completion of Placement and Exercise of Performance Rights
August 21, 2022
Proteomics raises $8m in highly successful Placement
August 14, 2022
Proteomics signs binding LOI with Sonic Healthcare USA
August 9, 2022
Clinical Utility Study demonstrates PromarkerD test benefits
August 1, 2022
Potential breakthrough blood test for endometriosis
July 31, 2022
June 2022 Quarterly Activities Report and Appendix 4C
July 27, 2022
European PromarkerD patents expanded beyond diabetes
July 24, 2022